Video

Dr. Morris on the significance of the emergence of 177Lu-PSMA-617 in prostate cancer

Video Player is loading.
Current Time 0:00
Duration 1:06
Loaded: 14.92%
Stream Type LIVE
Remaining Time 1:06
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Michael J. Morris, MD, discusses the rise of radiopharmaceuticals in prostate cancer and, in particular, the success of 177Lu-PSMA-617 (LuPSMA). Data from the phase 3 VISION trial presented at the 2021 ASCO Annual Meeting showed that adding Lu-PSMA-617 to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer. Morris, a medical oncologist and section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, was the lead study author on the VISION trial (J Clin Oncol 39, 2021 [suppl 15; abstr LBA4]).

    © 2025 MJH Life Sciences

    All rights reserved.